Eidos Therapeutics Inc (EIDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 191,157 | 157,147 | 5,497 | 1,956 |
| Receivables | 85 | 34 | 67 | 5 |
| TOTAL | $195,920 | $158,970 | $6,048 | $1,968 |
| Non-Current Assets | ||||
| PPE Net | 1,259 | 209 | 114 | N/A |
| Other Non-Current Assets | 6,641 | 933 | 181 | 7 |
| TOTAL | $7,900 | $1,142 | $295 | $7 |
| Total Assets | $203,820 | $160,112 | $6,343 | $1,975 |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 3,467 | 2,212 | 938 | 153 |
| Accrued Expenses | 6,409 | 2,577 | 1,300 | 140 |
| TOTAL | $10,430 | $4,789 | $2,238 | $293 |
| Non-Current Liabilities | ||||
| Long Term Debt | 16,112 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 5,851 | 316 | 273 | 360 |
| TOTAL | $21,963 | $316 | $273 | $360 |
| Total Liabilities | $32,393 | $5,105 | $2,511 | $653 |
| Shareholders' Equity | ||||
| Shares Outstanding, K | 38,510 | 36,819 | N/A | N/A |
| Common Shares | 38 | 37 | 4 | 3 |
| Retained earnings | -103,105 | -65,270 | -14,532 | -2,591 |
| Other shareholders' equity | 0 | 0 | 17,028 | 3,795 |
| TOTAL | $171,427 | $155,007 | $3,832 | $1,322 |
| Total Liabilities And Equity | $203,820 | $160,112 | $6,343 | $1,975 |